Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

Event · Earnings
Original reporting
Published Nov 12, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MNPR
Neutral
high confidence
Mentioned
$MNPR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MNPRNeutralMed
01

Why it matters

The 8‑K provides the first public disclosure of the rolling NDA submission status and baseline Phase 3 data, which are material for valuation.

02

Market read

The filing delivers fresh regulatory and financial data that can move MNPR and influence peer biotech stocks.

03

What to watch

The long‑term cash runway through 2028 provides runway for further development, and the neutral molybdenum safety data may de‑risk the program.

Relevance 7/10Novelty 8/10Timing: filed today (Nov 12) with immediate market impact

Background

Monopar Therapeutics is a clinical‑stage biopharma focused on Wilson disease with its lead candidate ALXN1840 in Phase 3 trials.

Company-level read

Ticker impact

$MNPRNeutralHigh confidence
Context

Monopar Therapeutics filed an 8‑K reporting Q3 2026 results, a $129.4M cash balance, increased R&D spend, and progress on the NDA rolling submission for ALXN1840.

Expected impact

potential modest upside as the NDA progress reduces regulatory risk, offset by pressure from higher losses and expense growth

Evidence & confidence

Positive regulatory update (rolling NDA) is material for a clinical‑stage biotech, while the deteriorating loss margin could limit upside.

Market effects

Highlights ongoing momentum in rare‑disease biotech pipelines and may lift peer valuations in the Wilson disease/rare‑disease space.

US biotech sector may see slight positive bias due to regulatory progress.

Limited to investors tracking clinical‑stage biopharma and FDA pipeline developments.

Counterpoint

The widening net loss and rising cash burn could signal financial strain, suggesting a short‑term downside despite regulatory progress.

Key entities

  • Monopar Therapeutics Inc.

    Nasdaq‑listed biotech developing ALXN1840 for Wilson disease.

  • Jeffrey D. Kent, M.D.

    New EVP, Head of Medical Affairs overseeing regulatory strategy.

Related articles

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRMedAI 8/10

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.

$MNPRLow

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.

$HDMedAI 8/10

Home Depot Just Delivered Great News to Investors

Home Depot (HD) reported its strongest same-store sales growth since Q3 2022, with 2.2% global and U.S. growth. CFO Richard McPhail becomes CEO, while Ted Decker transitions to chairman. Revenue rose 4.9% to $43.4B, and adjusted EPS increased 3% to $3.86. The company updated its full-year guidance, expecting 4.5% sales growth and 2% EPS increase. Management highlighted strength in professional and high-ticket sales.